US5147652A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Autobiotics and their use in eliminating nonself cells in vivo
Assignee: Cell Research Corp
•
Filing: 1990-07-03
•
Granted: 1992-09-15
•
Expires: 2010-07-03
Abstract
Abstract Physically and chemically latentiated autobiotics are described. The latentiated autobiotics are useful for the treatment or prevention of any disease or condition, which results from the presence of nonself cells in a vertebrate host. Latentiated autobiotics are furthermore useful in suppressing immune rejection processes, as radiosensitizers and as anticoagulants.
Inventors
- 👤 Laszlo G. Egyud
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 10:54
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/12; A61K31/121; A61K31/33; A61K31/395; A61K31/40; A61K31/4015; A61K9/00; A61K9/10; A61K9/127; A61P; A61P37/00; A61P43/00; Y; Y10; Y10S; Y10S436/00; Y10S436/829
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
38 words
A composition comprising an alpha-ketoaldehyde incapsulated in the lipid phase of a liposome, whereby its CO--CHO group extends outward from the exterior surface of the liposome, and a therapeutic compound encapsulated in the aqueous phase of the liposome.
Claim 2
Dependent Claim
38 words
A composition comprising an alpha-ketoaldehyde incapsulated in the lipid phase of a liposome, whereby its CO--CHO group extends outward from the exterior surface of the liposome, and a therapeutic compound encapsulated in the aqueous phase of the liposome.
Claim 3
Dependent Claim
43 words
A pharmaceutical composition comprising an alpha-ketoaldehyde incapsulated in the lipid phase of a liposome, whereby its CO--CHO group extends outward from the exterior surface of the liposome, a therapeutic compound encapsulated in the aqueous phase of the liposome and a pharmaceutically acceptable carrier.
Claim 4
Dependent Claim
43 words
A pharmaceutical composition comprising an alpha-ketoaldehyde incapsulated in the lipid phase of a liposome, whereby its CO--CHO group extends outward from the exterior surface of the liposome, a therapeutic compound encapsulated in the aqueous phase of the liposome and a pharmaceutically acceptable carrier.
Claim 5
Dependent Claim
26 words
A composition comprising an alpha-ketoaldehyde incapsulated in the lipid phase of a liposome, whereby its CO--CHO group extends outward from the exterior surface of the liposome.
Claim 6
Dependent Claim
26 words
A composition comprising an alpha-ketoaldehyde incapsulated in the lipid phase of a liposome, whereby its CO--CHO group extends outward from the exterior surface of the liposome.
Claim 7
Dependent Claim
14 words
A pharmaceutical which comprises the liposomes of claim 3 in a pharmaceutical composition carrier.
Claim 8
Dependent Claim
15 words
A pharmaceutical of claim 4 wherein the pharmaceutical composition carrier is compatible with topical application.
References Cited (Backward Citations)
US4066650A
Cited
US4529561A
Cited
US4241046A
Cited
US4440740A
Cited
WO1986001102A1
Cited
US4861588A
Cited
US4844904A
Cited
US4906477A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-09-15 | 1996-03-16 | 1996-09-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-09-15 | 2000-03-16 | 2000-09-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-09-15 | 2004-03-16 | 2004-09-15 | $7700.00 | Window Closed / Lapsed |